Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | CTC enumeration as a prognostic biomarker in prostate cancer

Howard Scher, MD, FASCO, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the development and validation of circulating tumor cell (CTC) enumeration, determined on the Epic Sciences platform, as a prognostic biomarker in men with metastatic castration-resistant prostate cancer (mCRPC). In the discovery cohort, CTC count was found to be a statistically significant prognostic factor of overall survival. These findings were then validated using data from the PROPHECY trial (NCT02269982). This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.